Loading stock data…
IQV
$157.77-0.60 (-0.38%)
Market ClosedLast close May 1
IQVIA Holdings Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
IQVIA Holdings Inc. in the Healthcare sector is trading at $157.77. The stock is currently 36% below its 52-week high of $247.05, remaining 19.9% below its 200-day moving average. Technical signals show neutral RSI of 34 and bearish MACD signal, explaining why IQV maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 34) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$157.77
Potential Upside
6.4%
Whystock Fair Value$167.85
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus20 analysts
Mean target$229.60+45.5%
Range$185.00 – $287.00
Fundamentals
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Techno...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$26.97B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.49
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.39
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.02%
Volume
Today's trading volume
1.52M
Recent News
A Look At IQVIA Holdings (IQV) Valuation After ESOP Linked Shelf Registration For Potential Share Issuance
ESOP linked shelf registration sets the stage for potential share issuance IQVIA Holdings (IQV) has filed a shelf registration for up to US$3.14b of common stock, covering 17,928,369 shares in an Employee Stock Ownership Plan related offering that could shape future equity issuance and dilution considerations. See our latest analysis for IQVIA Holdings. The ESOP linked shelf filing lands after a weak stretch for the share price, with a 7 day share price return of 9.51% and a 90 day share...
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 Healthcare Stock to Target This Week and 2 Facing Headwinds
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This has capped the upside for healthcare stocks lately as the industry’s flat return over the past six months has trailed the S&P 500’s 4.2% gain.
Can Eli Lilly’s Foundayo Catch Up to Novo’s Wegovy Pill?
Eli Lilly’s weight-loss pill appears to be falling behind oral Wegovy. Analysts say concerns are overblown.
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.